Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...
1 Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan 2 Department of Cardiovascular, University of Occupational and Environmental Health, Kitakyushu, ...
Patients on biosimilar adalimumab showed lower treatment success and faster loss of response compared to those on originator adalimumab. The study involved bio-naïve and switched cohorts, with ...
Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...
Yuflyma (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent hidradenitis suppurativa and pediatric uveitis. "Adolescent HS and ...
NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
The FDA previously approved YUFLYMA as a biosimilar to Humira ® for a variety of indications, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ...
INCHEON, South Korea, Oct. 17, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results